Uniplasty Inc (UPI) Thursday highlighted the results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment.
The medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions stated that the study compared percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC Neuromodulation System versus sacral nerve stimulation.
Melissa Martinson, PhD, lead author of the study stated, "This study demonstrates significant cost savings to the healthcare system when PTNS is used instead of SNS. In our current U.S. healthcare climate, maintaining the quality of care while also controlling costs is a central objective. We believe that studies like this can contribute to attaining that goal."
For comments and feedback: editorial@rttnews.com